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ARTICLE
A one-gate elevator mechanism for the human
neutral amino acid transporter ASCT2
Alisa A. Garaeva1, Albert Guskov 2, Dirk J. Slotboom 1,3 & Cristina Paulino 1,2
The human Alanine Serine Cysteine Transporter 2 (ASCT2) is a neutral amino acid
exchanger that belongs to the solute carrier family 1 (SLC1A). SLC1A structures have revealed
an elevator-type mechanism, in which the substrate is translocated across the cell membrane
by a large displacement of the transport domain, whereas a small movement of hairpin 2
(HP2) gates the extracellular access to the substrate-binding site. However, it has remained
unclear how substrate binding and release is gated on the cytoplasmic side. Here, we present
an inward-open structure of the human ASCT2, revealing a hitherto elusive SLC1A con-
formation. Strikingly, the same structural element (HP2) serves as a gate in the inward-facing
as in the outward-facing state. The structures reveal that SLC1A transporters work as one-
gate elevators. Unassigned densities near the gate and surrounding the scaffold domain, may
represent potential allosteric binding sites, which could guide the design of lipidic-inhibitors
for anticancer therapy.
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The Alanine Serine Cysteine Transporter 2 (ASCT2) belongsto the solute carrier family 1 (SLC1A) of transporters,which in mammals consists of the excitatory amino acid
transporters EAAT1–EAAT5 (SLC1A1-3, 6–7) and the neutral
amino acid transporters ASCT1-ASCT2 (SLC1A4-5)1. Although
EAATs and ASCTs share signiﬁcant similarities in sequence
(~40%) and structure2, they are mechanistically different: EAATs
typically concentrate the neurotransmitter L-glutamate against
its gradient3; whereas ASCTs catalyse the exchange of neutral
amino acids4.
Over the past years, ASCT2 has increasingly gained attention
as a potential target in anticancer therapy, as it is upregulated and
linked to poor survival in melanoma, lung, breast, prostate,
pancreatic, thyroid and colon cancer5–10. ASCT2 plays a role in
cancer cell growth by providing glutamine as an alternative car-
bon source for the tricarboxylic acid (TCA) cycle, for fatty-acid
production, and by contributing to the activation of the mam-
malian target of rapamycin complex (mTORC1)11. ASCT2 also
acts as a receptor for several retroviruses12, and a recently
determined structure2 revealed unique extracellular antennae that
likely form the required recognition platform13.
Structures of the prokaryotic SLC1A transporters GltPh and
GltTk and the human EAAT1 and ASCT2, in different con-
formational states, have provided insights into the transport
cycle14–19. They all share a similar homotrimeric protein archi-
tecture, where each protomer consists of a scaffold and a trans-
port domain. The scaffold domains provide the trimer interface
and do not move during the transport cycle. By contrast, each
transport domain located at the periphery binds the amino acid
and coupling ions, and translocates the substrates across the
membrane in an elevator-like manner. During this movement the
substrate is transported through the lipid bilayer in a fully
occluded state. Structures obtained in outward-open and
outward-occluded states, have revealed how the substrate reaches
the binding site from the extracellular side via a movement of
hairpin 2 (HP2)15,19. However, it remains unknown how binding
and release of the substrate occurs on the cytoplasmic side. The
structural pseudo-symmetry found within each protomer20, led
initially to the hypothesis that hairpin 1 (HP1), which is pseudo-
symmetry-related to HP2 would hinge and act as a gate at the
cytoplasmic side. As in such a transport mechanism the substrate
would pass through two different structural elements (HP1 and
HP2), it is referred to as the two-gate elevator mechanism.
Alternatively, the possibility that HP2 might also open from the
intracellular side (one-gate elevator mechanism) has been
discussed2,21. A deﬁnite answer to this key mechanistic question
can only be resolved by the structure of an inward-open state of
an SLC1A transporter. Here, we present cryo-EM structures of
ASCT2 with a single mutation in the binding site (ASCT2C467R)
in the presence and absence of its competitive inhibitor TBOA,
and of the substrate free wild-type ASCT2wt in the presence of
Na+. All structures capture an inward-open state, where HP2 has
moved indicating a one-gate elevator mechanism.
Results
Altering the substrate speciﬁcity of ASCT2. We recently
reported a cryo-EM structure of the human ASCT2 in a
glutamine-bound inward-occluded state2. We reckoned that
binding of bulkier substrates might prevent full occlusion and
capture the protein in an inward-open state—a strategy pre-
viously used to obtain the outward-open structures of GltPh and
EAAT1, where binding of DL-TBOA and TFB-TBOA prevented
closure of HP215,19. However, as ASCT2 does not transport
aspartate, these bulky aspartate analogues do not inhibit its
transport activity (Fig. 1a). A comparison of the substrate-binding
sites in the ASCT22 and the EAAT119 structures indicates that the
difference in substrate and inhibitor speciﬁcity might be largely
due to a single amino acid substitution, namely Cys467 in ASCT2
replacing Arg459 in EAAT1. It appears that the arginine residue
is the main determinant for acidic amino acid speciﬁcity, as the
guanidium group interacts with the side chain carboxylate of
glutamate and aspartate in transporters as GltPh, GltTk and
EAAT1. A substitution to a cysteine in EAAT3 has been shown to
abolish acidic amino-acid transport and instead introduced
neutral amino-acid speciﬁcity22. Based on this data, we
expected that the substitution of Cys467 in ASCT2 to arginine
might change its substrate speciﬁcity to acidic amino acids
and would allow inhibition by TBOA. We engineered this
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Fig. 1 Transport activity of reconstituted puriﬁed ASCT2wt (a) and ASCT2C467R (b). Curves show the counterﬂow of external radioactively-labelled and
internal unlabelled L-glutamine (squares, n= 6 for ASCT2wt, n= 3 for ASCT2C467R); counterﬂow of L-glutamine in presence of 0.6 mM DL-TBOA (upward
triangle, n= 4); counterﬂow of L-aspartate (circles, n= 3 for ASCT2wt, n= 5 for ASCT2C467R); and counterﬂow of L-aspartate in presence of 0.5 mM DL-
TBOA (downward triangles, n= 3). Data points and error bars represent means and s.e.m. from n biologically independent experiments. Small schemes
depict proteoliposomes with internal and external compound compositions used in respective experiments. Source data are provided as a Source Data ﬁle
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from Pichia pastoris and monitored its substrate uptake in pro-
teoliposomes. Indeed, the substrate speciﬁcity of ASCT2C467R
differed from that of the wild-type. ASCT2C467R did no longer
support glutamine uptake, but it transported aspartate instead
(Fig. 1b). Although the uptake rate of aspartate by ASCT2C467R
was slower than that of glutamine by ASCT2wt, the results
conﬁrm that a single point mutation in the substrate binding site
was sufﬁcient to switch the substrate speciﬁcity of ASCT2
from neutral to acidic amino acids. In addition, aspartate
transport could be suppressed by TBOA (Fig. 1b), which opened
the possibility to use the compound to trap the transporter in an
open state.
Cryo-EM structures of inward-open ASCT2. We determined the
structure of the 172-kDa trimeric ASCT2C467R in presence of
TBOA at 3.6 Å resolution by single particle cryo-EM (Fig. 2,
Supplementary Figs. 1 and 4, Table 1). The protein was embedded
in n-dodecyl-β-d-maltopyranoside (DDM) micelles supple-
mented with cholesterol hemisuccinate (CHS), which has been
shown to increase stability2. The quality of the cryo-EM map was
sufﬁcient to unambiguously model residues 43–159 and 177–489.
Notably, despite different strategies employed during image
processing, including 3D classiﬁcations with and without sym-
metry imposed on the trimer or single protomers, only a single
conformational state was captured for all protomers, indicating a
preferred state of the transporter in the given conditions (Sup-
plementary Fig. 1d). Strikingly, the ASCT2C467R structure reveals
an inward-open state of a SLC1A member (Figs. 3 and 4).
Compared to the previously determined substrate-bound inward-
occluded state of ASCT22, the most prominent difference is the
conformation of the loop connecting both helices of hairpin 2
(HP2 loop). It has hinged away from the glutamine-binding site
towards the scaffold domain by ~8 Å, opening a pathway to the
cytoplasm (Figs. 3a and Fig. 4a, b, Supplementary Movie 1).
Similar movements of the HP2 loop have been observed on the
extracellular side between the outward-occluded and outward-
open states of EAAT1 and GltPh structures15,19. Although the
remainder of the transport domain has virtually the same con-
formation as in the inward-occluded state (Fig. 3a), it is slightly
further tilted towards the cytoplasm, away from the scaffold
domain providing additional space for HP2 to open (Supple-
mentary Fig. 5a, Supplementary Movie 1).
In the substrate-binding site we observe a patch of non-protein
density close to R467. Although the density is too weak to allow
for an unambiguous assignment, it most likely represents a TBOA
molecule, although the occupancy of the site appears low
(Supplementary Fig. 5b). To test whether TBOA binding was
required to arrest the protein in the inward-open state, we further
determined a cryo-EM structure of ASCT2C467R in the absence of
its inhibitor. A 4.1 Å resolution cryo-EM map of substrate-free
ASCT2C467R shows a virtually identical inward-open state with a
displaced HP2 loop (Supplementary Figs. 2, 4 and 6a–c, Table 1).
This is surprising, as the binding of bulky inhibitors was required
to obtain all of the reported outward-open states of EAAT1 and
GltPh15,19,23. To exclude that the C467R mutation itself induced
the observed opening of HP2, we also investigated the










































Fig. 2 Inward-open structure of ASCT2C467R. Cryo-EM map of ASCT2C467R obtained in presence of TBOA at 3.6 Å resolution (a) and respective model
shown as ribbon (b). c Protomer of ASCT2 with labelled structural elements is shown as ribbon, rotations are indicated. The scaffold domains are coloured
in yellow, the extracellular antenna in red, the transport domains in blue, the HP2 loop in purple, and non-protein densities in grey (see also Supplementary
Fig. 7). The membrane boundary is indicated and the location of the substrate binding site as shown in Fig. 3 is highlighted by a black rectangle in panel b
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Data collection and processing
Magniﬁcation 49,407 49,407 49,407
Voltage (kV) 200 200 200
Electron exposure (e−/Å2) 52 52 52
Defocus range (μm) −0.8 to −1.8 −0.8 to −1.8 −0.8 to −1.8
Pixel size (Å) 1.012 1.012 1.012
Symmetry imposed C3 C3 C3
Initial particle images (no.) 987,852 245,367 317,611
Final particle images (no.) 223,354 23,664 19,651
Map resolution (Å) 3.61 4.13 6.98
FSC threshold 0.143 0.143 0.143
Map local resolution range (Å) 4.2–3.4 6.4–4.1 8.0–6.3
Reﬁnement
Initial model used PDB 6GCT PDB 6GCT –
Model resolution (Å) 3.6 4.1 –
(0.5 FSC threshold)
Model resolution range (Å) 15–3.6 15–4.1
Map sharpening B factor (Å2) −205 −211 −764
Model composition
Nonhydrogen atoms 9627 9627 –
Protein residues 1290 1290 –
Ligands 0 0 –
B factors (Å2)
Protein 19.03 83.05 –
Ligand – – –
R.m.s. deviations
Bond lengths (Å) 0.006 0.006 –
Bond angles (°) 0.979 1.023 –
Validation
MolProbity score 1.75 1.84 –
Clashscore 5.00 6.72 –
Poor rotamers (%) 0.29 0.49 –
Ramachandran plot
Favoured (%) 92.02 92.49 –
Allowed (%) 7.98 7.51 –















Fig. 3 Substrate-binding site and movement of the HP2 loop. a, b Superposition of the inward-open ASCT2C467R in presence of TBOA (shown in blue with
the HP2 loop in purple) and the substrate-bound inward-occluded ASCT2wt (shown in grey, PDB-ID: 6GCT), demonstrating the movement of HP2. b Non-
protein density (shown as red mesh at 3σ) located near HP1 and HP2 with a modelled diundecylphosphidylcholine and putatively coordinating residues
shown as sticks. The lipid head group is positioned between the HP1 and HP2 loops and its negative charge appears to be stabilised by the helix dipole of
hairpin helix HP2b. a, b Structures were superimposed on the transport domain
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glutamine. In the absence of substrate ASCT2wt appears to be less
stable and the obtained data suffered from lower particle quality
compared to ASCT2C467R. Albeit of lower resolution, the cryo-
EM map of the substrate-free ASCT2wt shows that the protein
accommodates the same inward-open state, where the HP2 loop
has moved (Supplementary Figs. 3 and 6d–f, Table 1). It appears
that an inward-open state of ASCT2 is favoured in the given
conditions without its respective substrate (L-glutamine in
ASCT2wt) added. Thus, neither the presence of the inhibitor
nor the point mutation itself is responsible for gate opening on
the intracellular side, allowing the use of the higher resolved
ASCT2C467R cryo-EM map for a detailed description of the
inward-open state.
Potential allosteric binding sites. In the cryo-EM maps of the
inward-open states of ASCT2C467R, an additional density is pre-
sent between the HP1 and HP2 tips (Figs. 3b and 4c). The
characteristic shape of this density indicates that it most likely
corresponds to a lipid molecule. The exact lipid identity is
ambiguous at the given resolution, but the tentatively modelled
diundecyl phosphatidylcholine ﬁts well in the density (Fig. 3b).
Notably, the head group occupies the position where the HP2
loop is located in the inward-occluded state, indicating that the
lipid would need to relocate for gate closure (Fig. 3). Consistently,
no lipid density was observed in the substrate-bound inward-
occluded ASCT2wt structure2.
Further unassigned densities were found between the transport
and scaffold domains (Figs. 2a and 4c and Supplementary Fig. 7).
The density at the interface between HP2 and TM2 of the scaffold
domain is located near the putatively bound cholesterols found in
the inward-occluded ASCT2 structure2 (Fig. 4c, Supplementary
Fig. 7a–c). However, as the position of HP2 in the inward-open
structure partly overlaps with the potential lipid densities found
in the inward-occluded structure, the previously assigned lipids
must relocate upon HP2 opening. Another patch of unassigned
density is located between the HP2 loop and TM1 and TM5
(Fig. 4c, Supplementary Fig. 7a, b, d, e). This putative lipid is
adjacent to the phosphatidylcholine found at the tip of both
hairpins described above (Figs. 3b and 4c, Supplementary Fig. 7a,
b, d, e). It might be responsible for the observed helix-
rearrangement of TM1 of the scaffold domain, which is not
directly interacting with HP2, when compared to the inward-
occluded ASCT2 structure2 (Supplementary Fig. 7e, Supplemen-
tary Movie 1). A large group of well deﬁned, unassigned densities,
which likely represent lipids or cholesterol molecules, is found in
the cavity formed by TM5 of one protomer, and TM2-4 and the
back of HP2 of the adjacent protomer (Fig. 4c, Supplementary
Fig. 7a, b, f). Interestingly, one of these densities is located at a
similar region as where the allosteric inhibitor UCPH101 binds
EAAT119, hinting at a potential regulatory role. Finally, a density
was found on the extracellular side of the scaffold domain. It is
located between the N- and C-termini of the ASCT2 antennae
(TM4b,c-loop) of two adjacent protomers (Supplementary Fig. 7a,
g), with distances to neighbouring side chains of ~4 Å. The shape
of the density suggests that it might represent a hydrated bound
ion, but it is not possible to unambiguously determine the identity
from the density map.
Discussion
The cryo-EM structures of the inhibitor-bound ASCT2C467R,
the substrate-free ASCT2C467R and the substrate-free ASCT2wt
presented here, reveal the hitherto elusive inward-open con-
formation of an SLC1A transporter. They show how HP2, and
not HP1, opens to provide access for binding and release of the
substrate on the cytoplasmic side of the membrane. Thus, ASCT2
functions as a one-gate elevator, where the HP2 loop serves as a
gate on both the extracellular and intracellular sides of the
membrane (Fig. 5, Supplementary Movie 1). Given the structural
similarity between ASCT2 and other SCL1A members, it is likely
that the same structural element constitutes the gate throughout
the family. These ﬁndings broaden our general understanding of
the transport mechanisms of secondary-active transporters.
Unique for SLC1A transporters, is that substrate binding and
release is gated via the same structural element, the substrate is
fully occluded inside the transport domain, which then moves in
an elevator-like mechanism from one side of the membrane to the
other (one-gate elevator mechanism). This contrasts, e.g., with
the well-characterised transport mechanisms of transporters
belonging to the major facilitator family (MFS) or the LeuT-fold
family24,25. In these families, the substrate becomes sandwiched
between two lobes or domains during the translocation, whereby
a rocking movement exposes different structural elements to the
extra- and intracellular sides of the membrane to gate the access
to the binding site (two-gate rocking mechanism).
Further, we were able to identify several non-protein densities
that likely correspond to lipid or cholesterol molecules. Putative
lipid molecules that directly and indirectly interact with the HP2
gate in the inward-open state (Figs. 2a, 3b and 4c, Supplementary
Fig. 7) will have to relocate to allow the transition to a substrate-
bound inward-occluded state. We thus predict that these sites are
potential allosteric binding sites that might affect the dynamics of
the transport cycle. The identiﬁcation of these sites could guide
the development of novel lipid-based drugs for cancer treatment.














Fig. 4 Accessibility of the substrate-binding site and lipid densities. a, b Surface representation of the ASCT2C467R structure in presence of TBOA, with the
transport domain in blue, the scaffold in yellow, the antennae in red, the HP2 loop in purple and TBOA in orange. The open HP2 gate provides access to the
binding site from the cytoplasm (indicated by arrows). c Slice through the surface representation of ASCT2C467R (level is indicated by dashed line in panel
a) with putative lipid densities surrounding the scaffold domain shown in black and TBOA as orange balls (see also Supplementary Fig. 7)
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Pichia pastoris found between the hairpins HP1 and HP2
(Fig. 3b) could be a potential target location for the development
of binders that could block ASCT2 activity and prevent glutamine
supply in cancer cells. Such lipid-like binders could act as inhi-
bitor, arresting the protein in the observed inward-open state
of ASCT2.
In conclusion, in light of the pharmacological relevance of
ASCT2 as a target in anticancer therapy, we anticipate that the
structure and mechanistic insights provided in this study may
offer new entry points for rational drug design.
Methods
ASCT2C467R engineering. The C467R single-point mutation was introduced using
QuickChange site-directed mutagenesis (forward primer 5′ GGTTGACAGATCTA
GAACCGTCTTGAACGTTG 3′; reverse primer 5′ CAACGTTCAAGACGGTTC
TAGATCTGTCAACC 3′) on the pPICZ-A plasmid, containing the codon opti-
mised human ASCT2 gene26. The obtained construct was sequenced (forward
primer 5′ GCGACTGGTTCCAATTGACAAGC 3′; reverse primer 5′ CAAATGG
CATTCTGACATCCTCTTG 3′), linearised and transformed into the Pichia pas-
toris X-33 strain by electroporation (Invitrogen). Colony selection was performed
on YPDS plates with increasing concentration of Zeocin (ThermoFisher Scientiﬁc),
namely 100, 1000 and 2000 μg/ml. Colonies from plates with the highest Zeocin
concentrations were further used for small-scale expression tests and the amount of
expressed ASCT2 was estimated by Western blot using antibodies against the His4-
tag (QIAGEN). ASCT2wt colonies grown at equivalent conditions were used as
positive control to compare protein expression levels. For screening, 10 ml of
BMGY medium were inoculated with a colony and incubated overnight at 30 °C in
a shaker at 200 rpm. Next morning cells were centrifuged at room temperature
(21 °C) for 10 min at 3000 × g, resuspended in 10 ml of BMMY (1% methanol)
medium and grown for 24 h at 30 °C in a shaker at 200 rpm. Cells were subse-
quently centrifuged at 4 °C for 10 min at 3000×g, washed with 10 ml of buffer A
(20 mM Tris-HCl pH 7.5, 100 mM NaCl, 0.5 mM EDTA, 5% w/v glycerol) and
resuspended in 500 μl lysis buffer (buffer A+ 1 mM PMSF and 0.1 mgml−1 DNase
A). Approximately 500 μl glass beads were added and cells were lysed using the
TissueLyser II (QIAGEN) for 5 min at 50 Hz. The lysed cells were centrifuged at
4 °C for 5 min at 11,700 × g, an additional 200 μl of lysis buffer was added to the
cells and the sample was centrifuged. The membrane fraction was obtained by
centrifugation of the supernatant for 1 h at 4 °C, 20,817 × g, resuspended in 40 μl
buffer A, ﬂash-frozen in liquid nitrogen and stored at −80 °C.
Protein expression and puriﬁcation. Large-scale ASCT2C467R protein over-
expression was carried out using bafﬂed ﬂasks27, whereas for ASCT2wt over-
production in a fermentor was used for cell cultivation26. Membrane fraction was
collected by ultracentrifugation of the supernatant (120 min, 193,727 g, 4 °C) after
breaking cells with a Constant Cell Disruption System (three passages at 39 kPsi,
5 °C)2. To purify ASCT2, an aliquot of membrane vesicles representing ~1.5 g cells
was solubilized in buffer B (25 mM Tris-HCl, pH 7.4, 300 mM NaCl, 10% (vol/vol)
glycerol, 1% DDM and 0.1% CHS (Anatrace)) for 1 h at 4 °C. After ultra-
centrifugation (30 min, 442,907 × g, 4 °C) the supernatant was incubated with
Ni2+-Sepharose resin for 1 h at 4 °C. The column was washed with buffer C
(20 mM Tris-HCl, pH 7.4, 300 mM NaCl, 50 mM imidazole, pH 7.4, 10% glycerol,
0.05% DDM and 0.005% CHS), and protein was eluted with buffer C containing
500 mM imidazole. Peak elution fraction was applied to size-exclusion chroma-
tography with a Superdex 200 10/300 gel-ﬁltration column (GE Healthcare)
preequilibrated with buffer D (20 mM Tris-HCl, pH 7.4, 300 mM NaCl, 0.05%
DDM and 0.005% CHS).
Reconstitution into proteoliposomes and transport assays. Freshly puriﬁed
ASCT2 was used for reconstitution into proteoliposomes as previously described in
presence of the indicated amino acid substrate2. The liposomes were composed of
Escherichia coli polar lipids and egg phosphatidylcholine at a 3:1 ratio (w/w) and
supplemented with 10% (w/w) cholesterol (Avanti Polar Lipids). For transport
assays with [3H] glutamine and [3H]aspartate (PerkinElmer), proteoliposomes
were loaded with 50 mM NaCl and 10 mM glutamine/aspartate using three freeze-
thawing cycles, then extruded 11 times through a 400-nm-diameter polycarbonate
ﬁlter (Avestin), diluted in buffer E (20 mM Tris pH 7.0) and ultracentrifuged for
45 min at 4 °C with 442,907 × g. Proteoliposomes were resuspended in minimal
volume of buffer E (~1 μg protein per 1.5 μl). The transport assay was carried out in
a water bath at 25 °C with constant stirring. The external substrate mixture (50 mM
NaCl and 50 μM [3H]glutamine/[3H]aspartate) was pre-warmed to the tempera-
ture of the assay. Transport was initiated by dilution of 1.5 μl proteoliposomes in
80 μl external buffer. At indicated time points the reaction was stopped by diluting
the mixture in 2 ml of cold buffer E, ﬁltered over a 0.45-μm pore-size ﬁlter (Portran
BA-85, Whatman), washed with 2 ml of cold buffer E and ﬁltered again. The level
of radioactivity accumulated inside the proteoliposomes, as a consequence of
amino-acid exchange, was counted using a PerkinElmer Tri-Carb 2800RT liquid
scintillation counter after dissolving the ﬁlter in 2 ml of scintillation liquid
(Emulsiﬁer Scintillator Plus, PerkinElmer).
Cryo-EM sample preparation and data collection. Freshly puriﬁed ASCT2C467R
(in mixed DDM+CHS micelles) was concentrated to ~5mgml−1 using an Amicon
Ultra-0.5mL concentrating device (Merck) with a 100 kDa ﬁlter cut-off. For the
cryo-EM data collection in presence of inhibitor, DL-threo-β-benzyloxyaspartic acid
(DL-TBOA) (Hello Bio) was added to the protein sample to a ﬁnal concentration of
1 mM prior to sample freezing. The ASCT2wt sample was freshly puriﬁed in absence
of amino acid substrate and concentrated to ~2 and ~8mgml−1. Holey-carbon cryo-
EM grids (Au R1.2/1.3, 300 mesh, Quantifoil) were glow discharged at 5 mA for 20 s.
2.8 μl protein sample were applied onto the grids, blotted for 3–5 s in a Vitrobot
Mark IV (Thermo Fisher) at 15 °C and 100% humidity, plunge frozen into a liquid
ethane/propane mixture and stored in liquid nitrogen until further use. Cryo-EM
data were collected in-house on a 200-keV Talos Arctica microscope (Thermo
Fisher) with a post-column energy ﬁlter (Gatan) in zero-loss mode, with a 20-eV slit
and a 100-μm objective aperture. Prior to data collection, the best regions on the grid
were identiﬁed with the help of a self-written script to calculate the ice thickness
(manuscript in preparation). Images were acquired in an automatic manner with
EPU (Thermo Fisher) on a K2 summit detector (Gatan) in counting mode at
×49,407 magniﬁcation (1.012 Å pixel size) and a defocus range from −0.8 to
−1.8 μm. During an exposure time of 9 s, 60 frames were recorded with a total dose
of about 52 electrons/Å2. During data collection the FOCUS software28 was used to
monitor data quality on-the-ﬂy and to adjust settings if necessary.
Image processing. For the ASCT2C467R dataset in presence of TBOA, 7327
micrographs were recorded. Beam-induced motion was corrected with Motion-
Cor2_1.1.029 and the CTF parameters estimated with ctfﬁnd4.1.830. Manual
selection of micrographs was carried out in FOCUS, whereby micrographs out of
defocus range (<0.4 and >2 µm), contaminated with ice or aggregates, and with a
low-resolution estimation of the CTF ﬁt (>5 Å), were discarded. The remaining
6698 micrographs were imported in RELION-3.0-beta-231 for further image pro-
cessing. Around 1200 particles were manually picked to calculate an initial tem-
plate for autopicking. After parameter optimisation 1,109,646 particles were












Fig. 5 One-gate elevator transport mechanism. Schematic representation of the transport cycle of SLC1A transporters, with the scaffold domain in yellow,
the transport domain in blue, the extra- and intracellular gate (HP2 loop) in purple and the transported amino acid in pink
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3D classiﬁcations allowed to select 375,596 high quality particles. The ﬁnal set of
particles was determined in a last round of 3D classiﬁcation with 6 classes, of which
the best particles clustered in one class with 223,354 particles (59.5%). These
particles were subjected to auto-reﬁnement, yielding a map of 4.12 Å. In the last
reﬁnement iteration, a mask excluding the micelle was used and the reﬁnement
continued until convergence (focus reﬁnement), which improved the resolution to
3.92 Å. During classiﬁcation and reﬁnement, a C3 symmetry was imposed. Initially,
the structure of ASCT2wt2 was used as a reference and in an iterative way, the new
obtained best map was used in subsequent rounds. References were low-pass ﬁl-
tered to 40 or 50 Å. The ﬁnal map was masked and sharpened during post-
processing resulting in a resolution of 3.68 Å. Finally, the newly available algorithm
of per-particle CTF reﬁnement and beam tilt reﬁnement in Relion331 was used on
re-extracted particles with a box size of 200 pixels to further improve the resolution
to 3.61 Å. Subtraction of the detergent micelle did not improve resolution. 3D
classiﬁcations without imposed symmetry as well as on individual protomers with
symmetry expansion and signal subtraction were performed at different levels of
image processing to check for conformational heterogeneity between and within
ASCT2 trimers. Local resolution estimations were determined in Relion. All
resolutions were estimated using the 0.143 cut-off criterion32 with gold-standard
Fourier shell correlation (FSC) between two independently reﬁned half-maps33.
During post-processing, the approach of high-resolution noise substitution was
used to correct for convolution effects of real-space masking on the FSC curve34.
The directional resolution anisotropy of density maps was quantitatively evaluated
using the 3DFSC web interface (https://3dfsc.salk.edu)35.
A similar approach was performed for the image processing of the ASCT2C467R
dataset in absence of TBOA. In short, 1605 micrographs were recorded, and 1479
used for image processing after selection. Over 323,403 particles were autopicked
and subjected to several rounds of 2D and 3D classiﬁcation. The ﬁnal data
comprising 23,367 particles yielded after reﬁnement and masking a map of 4.13 Å
resolution.
For the dataset of ASCT2wtin absence of substrate, in total 4305 micrographs
were recorded and 3272 micrographs were used for further image processing. After
manual particle picking, over 450,000 particles were autopicked and subjected to
several rounds of 2D and 3D classiﬁcation. The ﬁnal data comprising 19,651 particles
yielded after reﬁnement and masking a map of 6.98 Å resolution. 3D classiﬁcations
without imposed symmetry performed at different stages of image processing, as well
as a 3D classiﬁcation of individual protomers after symmetry expansion and signal
subtraction, yielded the same inward-open conformation of the protein.
Model building. Model building was carried out in COOT36 using the previously
determined ASCT2wt structure2 as reference. The resolution of the map was of
sufﬁcient quality to unambiguously assign the protein sequence and model most of
the residues (43–159, 177–489). After each round of real-space reﬁnement per-
formed in Phenix37 with NCS restrains, coordinates were manually inspected and
edited in COOT and submitted to another reﬁnement round in an iterative way.
The quality of the ﬁt was validated by a Fourier shell cross correlation (FSCsum)
between the reﬁned model and the ﬁnal map. To monitor the effects of potential
overﬁtting, random shifts (up to 0.5 Å) were introduced into the coordinates of the
ﬁnal model, followed by reﬁnement against the ﬁrst unﬁltered half map. The FSC
between this shaken-reﬁned model and the ﬁrst half map used during validation
reﬁnement is termed FSCwork, and the FSC against the second half map, which was
not used at any point during reﬁnement, is termed FSCfree. A marginal gap between
the curves describing FSCwork and FSCfree indicates no overﬁtting of the model. The
chemo-physical properties of the ﬁnal model were validated with MolProbity38.
The SBGrid software package tool was used39. Images were prepared with
PyMOL (The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC),
ChimeraX40, and a movie was made with Chimera41.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data supporting the ﬁndings of this manuscript are available from the corresponding
authors upon reasonable request. A reporting summary for this Article is available as
a Supplementary Information ﬁle.
The three-dimensional cryo-EM density maps of the inward-open ASCT2C467R in
presence of TBOA, the substrate-free ASCT2C467R and the substrate-free ASCT2wt have
been deposited in the Electron Microscopy Data Bank under accession numbers EMD-
10016, EMD-10018 and EMD-10017, respectively. The deposition includes the cryo-EM
maps, both half-maps, the unmasked and unsharpened reﬁned maps and the mask used
for ﬁnal FSC calculation. Coordinates of two models have been deposited in the Protein
Data Bank. The accession numbers for ASCT2C467R in presence of TBOA and substrate-
free ASCT2C467R are 6RVX and 6RVY, respectively. The source data underlying Fig. 1 are
provided as a Source Data ﬁle.
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